Estimated 2-year PFS2 with 2L BTKi in Relapsed/Refractory Mantle Cell Lymphoma.
The 2L BTKi MIPI is a prognostic index estimating 2-year progression-free survival in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who initiate second line (2L) covalent Bruton Tyrosine Kinase inhibitor (BTKi) monotherapy. The 2L BTKi MIPI is calculated using three variables that are readily available in routine clinical practice: time to progression of disease after first-line therapy, Ki67, and the Mantle Cell Lymphoma International Prognostic Index (MIPI).
The index generates three prognostic subgroups. On one extreme is a low-risk subgroup expected to derive long-term benefit from 2L BTKi. On the other extreme is a high-risk subgroup expected to derive very limited benefit from 2L BTKi, and in whom alternate treatment strategies should be rapidly and proactively planned. For example, these patients could be considered for chimeric antigen receptor T-cell therapy or allogeneic stem cell transplantation while their disease remains relatively controlled.
The 2L BTKi MIPI was developed in an international, multicenter cohort of 160 patients with R/R MCL consecutively treated with 2L BTKi across three different continents. It was validated in a cohort of 200 patients with R/R MCL consecutively treated with 2L ibrutinib in the United Kingdom.
D. Villa, A. Jiang, N. Crosbie, S. Rule, R. McCulloch et al,
The 2L BTKi MIPI is a prognostic index estimating 2-year progression-free survival in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who initiate second line (2L) covalent Bruton Tyrosine Kinase inhibitor (BTKi) monotherapy. The 2L BTKi MIPI is calculated using three variables that are readily available in routine clinical practice: time to progression of disease after first-line therapy, Ki67, and the Mantle Cell Lymphoma International Prognostic Index (MIPI).
The index generates three prognostic subgroups. On one extreme is a low-risk subgroup expected to derive long-term benefit from 2L BTKi. On the other extreme is a high-risk subgroup expected to derive very limited benefit from 2L BTKi, and in whom alternate treatment strategies should be rapidly and proactively planned. For example, these patients could be considered for chimeric antigen receptor T-cell therapy or allogeneic stem cell transplantation while their disease remains relatively controlled.
The 2L BTKi MIPI was developed in an international, multicenter cohort of 160 patients with R/R MCL consecutively treated with 2L BTKi across three different continents. It was validated in a cohort of 200 patients with R/R MCL consecutively treated with 2L ibrutinib in the United Kingdom.
D. Villa, A. Jiang, N. Crosbie, S. Rule, R. McCulloch et al,
© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.
